Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Guardant Health's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $533.0 Mil. Guardant Health's Total Assets for the quarter that ended in Mar. 2022 was $2,129.6 Mil.
Therefore, Guardant Health's Equity to Asset Ratio for the quarter that ended in Mar. 2022 was 0.25.
The historical rank and industry rank for Guardant Health's Equity-to-Asset or its related term are showing as below:
GH'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25 Med: 0.79 Max: 0.9
Current: 0.25
During the past 6 years, the highest Equity to Asset Ratio of Guardant Health was 0.90. The lowest was 0.25. And the median was 0.79.
GH's Equity-to-Asset is ranked worse than 85.66% of 244
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.63
vs GH: 0.25
Guardant Health Equity-to-Asset Historical Data
The historical data trend for Guardant Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Equity-to-Asset
0.90
0.82
0.83
0.57
0.29
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Equity-to-Asset
0.36
0.34
0.32
0.29
0.25
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Equity-to-Asset Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Guardant Health's Equity-to-Asset falls into.
Guardant Health Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Guardant Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Guardant Health Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Guardant Health's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.48(1.31%) Volume: 308,340 10:17AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
